DS
LFCR icon

David Shaw’s Lifecore Biomedical LFCR Stock Holding History

David Shaw’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,428
Closed -$306K – 4816
2025
Q4 		$306K Buy
+37,428
New +$277K ﹤0.01% 4139
2023
Q1 		– Sell
-47,971
Closed -$311K – 4680
2022
Q4 		$311K Buy
47,971
+1,568
+3% +$12.9K ﹤0.01% 4072
2022
Q3 		$413K Sell
46,403
-4,065
-8% -$41.3K ﹤0.01% 4151
2022
Q2 		$503K Sell
50,468
-14,342
-22% -$142K ﹤0.01% 4082
2022
Q1 		$750K Buy
64,810
+10,219
+19% +$114K ﹤0.01% 4128
2021
Q4 		$606K Buy
54,591
+767
+1% +$7.44K ﹤0.01% 4289
2021
Q3 		$496K Sell
53,824
-47,508
-47% -$517K ﹤0.01% 4087
2021
Q2 		$1.14M Buy
101,332
+60,011
+145% +$692K ﹤0.01% 3431
2021
Q1 		$438K Sell
41,321
-2,962
-7% -$33.3K ﹤0.01% 3566
2020
Q4 		$480K Buy
44,283
+28,432
+179% +$294K ﹤0.01% 3410
2020
Q3 		$154K Sell
15,851
-1,234
-7% -$11.8K ﹤0.01% 3645
2020
Q2 		$136K Sell
17,085
-6,522
-28% -$67.3K ﹤0.01% 3854
2020
Q1 		$205K Sell
23,607
-46,833
-66% -$487K ﹤0.01% 3637
2019
Q4 		$797K Buy
70,440
+37,748
+115% +$402K ﹤0.01% 3132
2019
Q3 		$355K Buy
+32,692
New +$356K ﹤0.01% 3370
2019
Q2 		– Sell
-23,068
Closed -$283K – 3763
2019
Q1 		$283K Buy
23,068
+12,648
+121% +$154K ﹤0.01% 3245
2018
Q4 		$123K Sell
10,420
-11,689
-53% -$161K ﹤0.01% 3617
2018
Q3 		$318K Buy
22,109
+8,037
+57% +$111K ﹤0.01% 3334
2018
Q2 		$210K Buy
+14,072
New +$196K ﹤0.01% 3540
2018
Q1 		– Sell
-17,580
Closed -$222K – 3644
2017
Q4 		$222K Buy
17,580
+574
+3% +$7.25K ﹤0.01% 3387
2017
Q3 		$220K Buy
+17,006
New +$224K ﹤0.01% 3275
2017
Q2 		– Sell
-11,202
Closed -$134K – 3464
2017
Q1 		$134K Sell
11,202
-16,558
-60% -$210K ﹤0.01% 3173
2016
Q4 		$383K Buy
27,760
+11,371
+69% +$158K ﹤0.01% 3000
2016
Q3 		$220K Buy
+16,389
New +$199K ﹤0.01% 3169
2016
Q1 		– Sell
-26,672
Closed -$316K – 3624
2015
Q4 		$316K Sell
26,672
-239
-0.9% -$2.94K ﹤0.01% 3340
2015
Q3 		$314K Buy
+26,911
New +$357K ﹤0.01% 3328

Other funds holding LFCR

2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GC
Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's LFCR Position: Q1 2026 in Review

David Shaw sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 37,428 shares — an estimated $306K sold.

David Shaw first reported a position in LFCR in Q3 2015 and held it in 26 quarters. The position peaked at $1.14M in Q2 2021. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • David Shaw reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
  • David Shaw sold 37,428 Lifecore Biomedical shares in Q1 2026, an estimated $306K.
  • David Shaw first reported a position in Lifecore Biomedical in Q3 2015 and held it in 26 quarters.
  • David Shaw's Lifecore Biomedical position peaked at $1.14M in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.